BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9353363)

  • 1. Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor.
    Clark MJ; Emmerson PJ; Mansour A; Akil H; Woods JH; Portoghese PS; Remmers AE; Medzihradsky F
    J Pharmacol Exp Ther; 1997 Nov; 283(2):501-10. PubMed ID: 9353363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
    Szekeres PG; Traynor JR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
    Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta opioid receptor down-regulation is independent of functional G protein yet is dependent on agonist efficacy.
    Remmers AE; Clark MJ; Liu XY; Medzihradsky F
    J Pharmacol Exp Ther; 1998 Nov; 287(2):625-32. PubMed ID: 9808689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of three separate guanine nucleotide-binding proteins that interact with the delta-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells.
    Roerig SC; Loh HH; Law PY
    Mol Pharmacol; 1992 May; 41(5):822-31. PubMed ID: 1317000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of delta opioid receptor in neuroblastoma NS20Y: receptor activation and neuroblastoma proliferation.
    Law PY; Bergsbaken C
    J Pharmacol Exp Ther; 1995 Jan; 272(1):322-32. PubMed ID: 7815347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
    Childers SR; Fleming LM; Selley DE; McNutt RW; Chang KJ
    Mol Pharmacol; 1993 Oct; 44(4):827-34. PubMed ID: 8232233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE.
    Allouche S; Polastron J; Hasbi A; Homburger V; Jauzac P
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):71-8. PubMed ID: 10432302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
    Prather PL; Tsai AW; Law PY
    J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
    Remmers AE; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1999 Feb; 288(2):827-33. PubMed ID: 9918595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-truncated delta-opioid receptor underwent agonist-dependent activation and desensitization.
    Wang C; Zhou D; Cheng Z; Wei Q; Chen J; Li G; Pei G; Chi Z
    Biochem Biophys Res Commun; 1998 Aug; 249(2):321-4. PubMed ID: 9712694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.
    Chakrabarti S; Yang W; Law PY; Loh HH
    Mol Pharmacol; 1997 Jul; 52(1):105-13. PubMed ID: 9224819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
    Merkouris M; Dragatsis I; Megaritis G; Konidakis G; Zioudrou C; Milligan G; Georgoussi Z
    Mol Pharmacol; 1996 Oct; 50(4):985-93. PubMed ID: 8863845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postnatal development of delta-opioid receptor subtypes in mice.
    Negri L; Severini C; Lattanzi R; Potenza RL; Melchiorri P
    Br J Pharmacol; 1997 Mar; 120(6):989-94. PubMed ID: 9134207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
    Knapp RJ; Santoro G; De Leon IA; Lee KB; Edsall SA; Waite S; Malatynska E; Varga E; Calderon SN; Rice KC; Rothman RB; Porreca F; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1284-91. PubMed ID: 8667189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
    Newman-Tancredi A; Cussac D; Audinot V; Pasteau V; Gavaudan S; Millan MJ
    Mol Pharmacol; 1999 Mar; 55(3):564-74. PubMed ID: 10051542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.